An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer resistance.
01. To meet the need in targeting treatment resistance
02. To meet the need in breaking immunue tolerance
in colorectal cold and hot mice model
in several model
GM-CSF low dose: Recruits APC at injection point and mature DCs.
Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation
Chemokyne cytokine TLR : Increase trafficking of T cell
Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors
5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy. Decrease the activity of immunosuppressive cells (Tregs and MDSCs)
Checkpoint inhibitors, ADC, BiSpecific mAb, TLR restores the anticancer immunity